MDCO » Topics » Item 2.02. Results of Operations and Financial Condition.

This excerpt taken from the MDCO 8-K filed Oct 22, 2008.

Item 2.02.  Results of Operations and Financial Condition.

 

On October 22, 2008, The Medicines Company (the “Company”) announced financial results for the quarter and nine-month period ended September 30, 2008.  The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

This excerpt taken from the MDCO 8-K filed Jul 23, 2008.

Item 2.02.  Results of Operations and Financial Condition.

 

On July 23, 2008, The Medicines Company (the “Company”) announced financial results for the quarter and six-month period ended June 30, 2008.  The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

This excerpt taken from the MDCO 8-K filed Feb 13, 2008.

Item 2.02.  Results of Operations and Financial Condition.

 

On February 13, 2008, The Medicines Company (the “Company”) announced financial results for the year and quarter ended December 31, 2007.  The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

This excerpt taken from the MDCO 8-K filed Oct 24, 2007.

Item 2.02. Results of Operations and Financial Condition.

 

On October 24, 2007, The Medicines Company (the “Company”) announced financial results for the quarter and nine-month period ended September 30, 2007. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

This excerpt taken from the MDCO 8-K filed Jul 25, 2007.

Item 2.02.  Results of Operations and Financial Condition.

On July 25, 2007, The Medicines Company (the “Company”) announced financial results for the quarter and six month period ended June 30, 2007.  The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

This excerpt taken from the MDCO 8-K filed Jul 2, 2007.

Item 2.02.  Results of Operations and Financial Condition.

On July 2, 2007, The Medicines Company (the “Company”) announced that it expects net revenue for the quarter ended June 30, 2007 to be in the range of $56 million to $58 million.

Statements contained in this Form 8-K about The Medicines Company that are not purely historical, and all other statements that are not purely historical, may be deemed to be forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, the words “believes,” “anticipates” and “expects” and similar expressions are intended to identify forward-looking statements and all statements as to revenue are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company’s actual results, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. For example, the revenue results for the quarter ended June 30, 2006 are preliminary and subject to change.  Important factors that may cause or contribute to such differences include the extent of the commercial success of Angiomax, the impact of FAS 123R on our financial results, the impact of government regulation on the Company’s business and the effects of exchange rate fluctuations and other international economic, political and other risks, and such other factors as are set forth in the risk factors detailed from time to time in the Company’s periodic reports and registration statements filed with the Securities and Exchange Commission including, without limitation, the risk factors detailed in the Company’s Quarterly Report on Form 10-Q filed on May 9, 2007, which are incorporated herein by reference. The Company specifically disclaims any obligation to update these forward-looking statements. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.

The information in this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

THE MEDICINES COMPANY

 

 

 

 

 

 

 

 

 

 

Date:  July 2, 2007

 

By:

 

/s/ Paul M. Antinori

 

 

 

 

 

Paul M. Antinori

 

 

 

 

Senior Vice President and General Counsel

 

2



This excerpt taken from the MDCO 8-K filed Apr 18, 2007.

Item 2.02.  Results of Operations and Financial Condition.

On April 18, 2007, The Medicines Company (the “Company”) announced financial results for the quarter ended March 31, 2007.  The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

This excerpt taken from the MDCO 8-K filed Feb 14, 2007.

Item 2.02.  Results of Operations and Financial Condition.

On February 14, 2007, The Medicines Company (the “Company”) announced financial results for the quarter and year ended December 31, 2006.  The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

This excerpt taken from the MDCO 8-K filed Jan 16, 2007.

Item 2.02.   Results of Operations and Financial Condition.

On January 16, 2007, The Medicines Company (the “Registrant”) stated in a preliminary supplement (the “Prospectus Supplement”) to the prospectus included in the automatic shelf registration statement described in Item 7.01 below that it expected to report net revenues of approximately $60.3 million for the three months ended December 31, 2006 and net revenues of approximately $213.9 for the year ended December 31, 2006.

This excerpt taken from the MDCO 8-K filed Oct 25, 2006.

Item 2.02.  Results of Operations and Financial Condition.

On October 25, 2006, The Medicines Company (the “Company”) announced financial results for the quarter and nine months ended September 30, 2006.  The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

This excerpt taken from the MDCO 8-K filed Jul 25, 2006.

Item 2.02.  Results of Operations and Financial Condition.

On July 25, 2006, The Medicines Company (the “Company”) announced financial results for the quarter ended June 30, 2006.  The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

This excerpt taken from the MDCO 8-K filed Apr 19, 2006.

Item 2.02. Results of Operations and Financial Condition.

 

On April 19, 2006, The Medicines Company (the “Company”) announced financial results for the quarter ended March 31, 2006. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki